ApolloMed And Helynx Announce Deployment Of Next-Generation Machine Learning Predictive Analytics Platform
GLENDALE, Calif., Nov. 10, 2015 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed" or "the Company") (AMEH), an integrated population health management company, and Helynx, Inc., today announced the deployment of a next-generation machine learning predictive analytics platform.
The two companies are teaming up to improve the medical outcomes of patients in ApolloMed's Accountable Care Organization (ApolloMed ACO) and IPA (Maverick IPA). The effort will combine claims and clinical data from ApolloMed with Helynx's unprecedented analytics platform. Helynx combines a vast array of information into a single, flexible format (a graph database), and employs machine learning to build a model from the combined data, facilitating data-driven predictions. The field of machine learning evolved from the study of pattern recognition and computational learning theory in artificial intelligence, and allows computers to find hidden insights without being explicitly programmed where to look.
ApolloMed will use Helynx's cloud-based analytics engine to:
- Identify those patients at highest risk of being admitted to the hospital.
- Identify those patients at highest risk of hospital readmissions.
- Estimate hospital lengths of stay.
- Predict high cost cases.
- Risk-stratify patients.
- Compare patient's actual costs and outcomes to their risk-adjustment factor ("RAF")-based scores.
- Using Helynx's patent-pending design, explore ApolloMed's data to reveal valuable patterns or anomalies.
Helynx was founded by Chess Stetson, PhD and Boris Revechkis, PhD. Borne out of their academic background with neural recordings, Helynx's technology was presented at the 2nd Annual Summit on Risk Adjustment and Revenue Management in December 2014 in Carlsbad, California and won 1st Place at the Herox Clinical Trials Innovation Challenge sponsored by the Bonnie J. Addario Lung Cancer Foundation in August 2015. Dr. Stetson and Dr. Revechkis both earned their PhDs in Computation and Neural Systems at Caltech. They are joined by Kris Chaisanguanthum, PhD, who earned a PhD in Physics from Harvard. Diane Pham, M.D., Senior Medical Informatics Analyst at ApolloMed, will work with the Helynx team on this project.
"We believe that big data analytics will play a transformative role in healthcare in the near future and especially in population health management. Helynx's unique machine-learning predictive analytics platform will help us further identify our highest risk patients so we can assign care managers and clinicians to them and intervene in their care before they deteriorate," stated Warren Hosseinion, M.D., Chief Executive Officer of Apollo Medical Holdings. "These interventions should significantly reduce avoidable hospitalizations, improve patient outcomes and save millions of dollars in healthcare costs."
"We are excited to provide ApolloMed an enhanced ability to identify high-risk patients," stated Dr. Stetson, Chief Executive Officer of Helynx, Inc. "Many current predictive algorithms in healthcare are based on traditional clinical knowledge, which can be highly effective. Yet increasingly, we can use large amounts of high-dimensional data to improve these predictions. And for us, the really exciting thing can be finding patterns in the data that we didn't expect."
About Apollo Medical Holdings, Inc. (ApolloMed)
Headquartered in Glendale, California, ApolloMed is a leading integrated population health management company committed to providing exceptional multi-disciplinary care in the communities it serves. ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated healthcare delivery platform comprised of six affiliated and complementary physician groups: ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group (Independent Physician Association), AKM Medical Group (IPA), ApolloMed Care Clinics and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care. For more information, please visit www.apollomed.net
About Helynx, Inc.
Based in Pasadena, California, Helynx is a startup company specializing in data analytics for science and medicine. The Helynx software is a first-of-its kind analytics environment that encodes data -- providers, anonymized patients, diseases, procedures and even the analyst's own behavior -- in a flexible, schema-free, secure graph database. This patent-pending approach allows visual interaction with the data at any scale, as well as modeling, statistical analysis, and machine learning-- all without writing code or SQL queries. Helynx's goal is to reveal patterns in healthcare data that can help providers and payers optimize costs and improve quality of care for their patients. www.helynx.com.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of Apollo Medical Holdings, Inc. ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. Some factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company's Annual Report on our amended Form 10-K for the fiscal year ended March 31, 2015, under the caption "Risk Factors", which is on file with the Securities and Exchange Commission and available in the "Investor" section of the Company's website under the heading "SEC Filings". The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Apollo Medical Holdings, Inc.
FOR MORE INFORMATION, PLEASE CONTACT:
Michael Sullivan
RedChip Companies Inc.
1-800-733-2447 Ext. 115
[email protected]
SOURCE Apollo Medical Holdings, Inc.
Share this article